Literature DB >> 16915375

Rituximab-induced long-term remission in two children with SLE.

Annette Friederike Jansson1, Uwe Wintergerst, Ellen D Renner, Bernd H Belohradsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16915375     DOI： 10.1007/s00431-006-0217-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  6 in total

1.  B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.

Authors:  Stephen D Marks; Sue Patey; Paul A Brogan; Nathan Hasson; Clarissa Pilkington; Patricia Woo; Kjell Tullus
Journal:  Arthritis Rheum       Date:  2005-10

2.  B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

Authors:  M J Leandro; G Cambridge; J C Edwards; M R Ehrenstein; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2005-09-27       Impact factor: 7.580

Review 3.  Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.

Authors:  Petros P Sfikakis; John N Boletis; George C Tsokos
Journal:  Curr Opin Rheumatol       Date:  2005-09       Impact factor: 5.006

4.  Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report.

Authors:  Monika Edelbauer; Therese Jungraithmayr; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2005-03-17       Impact factor: 3.714

5.  B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity.

Authors:  O T Chan; M P Madaio; M J Shlomchik
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

Review 6.  Rituximab: a promising therapy in systemic lupus erythematosus.

Authors:  Akaluck Thatayatikom; Andrew J White
Journal:  Autoimmun Rev       Date:  2005-06-13       Impact factor: 9.754
  6 in total
  4 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

2.  B cell depletion for autoimmune diseases in paediatric patients.

Authors:  Annette F Jansson; Claudia Sengler; Jasmin Kuemmerle-Deschner; Bernd Gruhn; A Birgitta Kranz; Hartwig Lehmann; Daniela Kleinert; Lars Pape; Hermann J Girschick; Ivan Foeldvari; Dieter Haffner; Johannes P Haas; Dagmar Moebius; Dirk Foell; Joachim Peitz; Veit Grote
Journal:  Clin Rheumatol       Date:  2010-12-01       Impact factor: 2.980

3.  [B-cell targeted therapy for children and adolescents with rheumatic diseases].

Authors:  H Morbach; H J Girschick
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

4.  Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

Authors:  Vivek L Patel; Matthieu Mahévas; Soo Y Lee; Roberto Stasi; Susanna Cunningham-Rundles; Bertrand Godeau; Julie Kanter; Ellis Neufeld; Tillmann Taube; Ugo Ramenghi; Shalini Shenoy; Mary J Ward; Nino Mihatov; Vinay L Patel; Philippe Bierling; Martin Lesser; Nichola Cooper; James B Bussel
Journal:  Blood       Date:  2012-05-07       Impact factor: 22.113
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.